Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.

Item

http://www.wikidata.org/entity/Q38416536

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.

@en

type

Item

label

Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.

@en

prefLabel

Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.

@en

P1476

Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.

@en

P2093

Adewale O Adebajo

http://www.w3.org/2001/XMLSchema#string

Alvin Wells

http://www.w3.org/2001/XMLSchema#string

Christopher Edwards

http://www.w3.org/2001/XMLSchema#string

Hunar Abdulrahim

http://www.w3.org/2001/XMLSchema#string

Samuel Thistleton

http://www.w3.org/2001/XMLSchema#string

Tim Shaw

http://www.w3.org/2001/XMLSchema#string

P2860

Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis

Keynote review: phosphodiesterase-4 as a therapeutic target

Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling

Cilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease.

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies.

Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.

Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling.

Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells.

P304

1099-1108

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2015.1034107

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25864487

http://www.w3.org/2001/XMLSchema#string